ホーム › 非小細胞肺癌 › コロンビア特別区 › Washington
Washington、DCにおける非小細胞肺癌の臨床試験
Washingtonとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する55件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- 他1件
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
被験者募集中観察研究
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Local Institution - 0183, Washington D.C.
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
被験者募集中第3相
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
A Study of PHN-012 in Patients With Advanced Solid Tumors
被験者募集中第1相
- PHN-012-001 Site, Washington D.C.
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
被験者募集中第2相
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
被験者募集中観察研究
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Maryland Oncology Hematology, P.A., Silver Spring · 7マイル先
- Maryland Oncology Hematology, P.A., Bethesda · 7マイル先
- Maryland Oncology Hematology, P.A, Largo · 11マイル先
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
被験者募集中第2相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
被験者募集中第3相
- Research Site, Silver Spring · 7マイル先
- Research Site, Bethesda · 7マイル先
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Maryland Oncology Hematology, P.A., Silver Spring · 7マイル先
- Maryland Oncology Hematology, P.A., Bethesda · 7マイル先
- Maryland Oncology Hematology, P.A., Largo · 11マイル先
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- MedStar Georgetown University Hospital, Washington D.C.
- Washington DC VA Medical Center, Washington D.C.
- Maryland Oncology Hematology P A, Silver Spring · 7マイル先
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Georgetown University, Washington D.C.
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
被験者募集中第3相
- Washington DC Veterans Affairs Medical Center, Washington D.C.
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
被験者募集中第2相
- MedStar Georgetown University Hospital, Washington D.C.
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- Sibley Memorial Hospital, Washington D.C.
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
被験者募集中第1相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
被験者募集中第2/3相
- MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH), Washington D.C.
- MEDSTAR Washington Hospital Center (MedStar Health Research Institute), Washington D.C.
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Georgetown University Medical Center, Washington D.C.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, Bethesda · 7マイル先
- Research Site, Bethesda · 7マイル先
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
被験者募集中第3相
- George Washington University Cancer Center, Washington D.C.
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
被験者募集中第1/2相
- Georgetown University Lombardi Cancer Center, Washington D.C.
- Sibley Memorial Hospital, Washington D.C.
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
被験者募集中第2/3相
- Local Institution - 007-5476, Washington D.C.
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington D.C.
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Sibley Memorial Hospital, Washington D.C.
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- Walter Reed National Military Medical Center, Bethesda · 7マイル先
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
被験者募集中第3相
- Washington Hospital Center ( Site 0037), Washington D.C.
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
被験者募集中第2相
- National Institutes of Health Clinical Center, Bethesda · 7マイル先
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
被験者募集中第3相
- Research Site, Bethesda · 7マイル先
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
被験者募集中第2相
- MedStar Georgetown University Hospital, Washington D.C.
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Sibley Memorial Hospital, Washington D.C.
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
被験者募集中第3相
- Sibley Memorial Hospital, Washington D.C.
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- National Institutes of Health, Bethesda · 7マイル先
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
被験者募集中第1/2相
- Georgetown University - Lombardi Comprehensive Cancer Center, Washington D.C.
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
被験者募集中第1/2相
- Georgetown University Medical Center, Washington D.C.
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
被験者募集中第2相
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
被験者募集中第1/2相
- Georgetown University, Washington D.C.
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
被験者募集中第1相
- Maryland Oncology Hematology, Calverton · 12マイル先
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
被験者募集中第1/2相
- Georgetown University Medical Center, Washington D.C.
Gilteritinib for the Treatment of ALK NSCLC
被験者募集中第1相
- Georgetown University, Washington D.C.
Study of XB010 in Subjects With Solid Tumors
被験者募集中第1相
- Georgetown University Medical Center, Washington D.C.
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11マイル先
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
被験者募集中第2相
- USA11-0, Bethesda · 7マイル先
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
被験者募集中第3相
- Georgetown University Medical Cener (GUMC), Washington D.C.
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Research Site, Washington D.C.
- Research Site, Bethesda · 7マイル先
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11マイル先
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11マイル先
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
被験者募集中第1/2相
- Sibley Memorial Hospital, Washington D.C.
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
被験者募集中第2相
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
- Medstar Washington Hospital Center, Washington D.C.
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
被験者募集中第1相
- National Cancer Institute, Bethesda · 7マイル先
Repositioning Immunotherapy in VetArans With Lung Cancer
被験者募集中第2相
- VA Central Office, Washington, DC, Washington D.C.
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- The Center for Cancer and Blood Disorder, Bethesda · 7マイル先
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
被験者募集中第1/2相
- The George Washington University Cancer Center (site 212), Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Silver Spring · 7マイル先
- Massive Bio SYNERGY-AI site, Bethesda · 7マイル先
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
被験者募集中第1/2相
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Seattle, WA53件の研究
Washingtonにおける他の研究
- がん（全種類）58件の研究
- 乳がん46件の研究
- 転移性癌43件の研究
- 肺がん41件の研究
- 前立腺がん38件の研究
- 肥満症33件の研究
- 大腸癌29件の研究
- 心血管疾患28件の研究
- 膀胱癌26件の研究
- 急性骨髄性白血病24件の研究
- 卵巣がん23件の研究
- リンパ腫23件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。